title: Does histologic subtype affect oncologic outcomes after nephron-sparing surgery?
abstract: OBJECTIVE
  To test whether renal cell carcinoma (RCC) histologic subtypes (HSs) affect cancer-specific mortality after nephron-sparing surgery (NSS). HSs are considered of prognostic value in RCC. For example, the papillary HS might confer a worse prognosis, and, at some centers, only radical nephrectomy is performed for the papillary HS.
  
  
  METHODS
  We used univariate and multivariate Cox regression models to study patients with Stage T1N0M0 RCC treated with NSS (n = 1205) from 1988 to 2004. The data were taken from 9 Surveillance, Epidemiology, and End Results registries.
  
  
  RESULTS
  At 36 months after NSS, the cancer-specific mortality rate was 97.8%, 100%, and 97.4% for a clear cell, chromophobe, and papillary RCC HS, respectively. On univariate and multivariate analyses, no statistically significant differences were recorded with regard to the HS.
  
  
  CONCLUSIONS
  Despite the suggested more aggressive phenotype of the papillary HS, we found no difference among the papillary, chromophobe, and clear cell variants. Thus, the diagnosis of one HS vs another HS should not deter from the use of NSS when cancer-specific mortality is considered as an endpoint.
authors.affiliation: Cancer Prognostics and Health Outcomes Unit, University of Montreal, Montreal, Quebec, Canada.
authors.forename: Maxime
authors.initials: M
authors.lastname: Crépel
authors.forename: Hendrik
authors.initials: H
authors.lastname: Isbarn
authors.forename: Umberto
authors.initials: U
authors.lastname: Capitanio
authors.forename: Daniel
authors.initials: D
authors.lastname: Liberman
authors.forename: Claudio
authors.initials: C
authors.lastname: Jeldres
authors.forename: Maxine
authors.initials: M
authors.lastname: Sun
authors.forename: Shahrokh F
authors.initials: SF
authors.lastname: Shariat
authors.forename: Hugues
authors.initials: H
authors.lastname: Widmer
authors.forename: Philippe
authors.initials: P
authors.lastname: Arjane
authors.forename: Markus
authors.initials: M
authors.lastname: Graefen
authors.forename: Francesco
authors.initials: F
authors.lastname: Montorsi
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Patard
authors.forename: Paul
authors.initials: P
authors.lastname: Perrotte
authors.forename: Pierre I
authors.initials: PI
authors.lastname: Karakiewicz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002292:Carcinoma, Renal Cell / Q000145:classification / Q000473:pathology* / Q000601:surgery*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000145:classification / Q000473:pathology* / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy / Q000379:methods*; D009399:Nephrons; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult